Vertex Pharmaceuticals (VRTX) EVP Tatsis reports 4,500-share insider sale

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Dr. Ourania Tatsis reported an open market sale of company stock. On 12/03/2025, she sold 4,500 shares of Vertex common stock at a weighted average price of $449.99 per share, with individual sale prices ranging from $449.99 to $450.00. The transaction was coded as an open market sale and was made under a company-approved Rule 10b5-1 trading plan that Dr. Tatsis entered into on 08/21/2025. After this sale, she beneficially owned 46,793 shares of Vertex common stock directly.

Insider Trade Summary

Net Seller: 4,500 shares ($2,024,955)

Net Sell 1 txn

Insider Tatsis Ourania

Role EVP, Chief Reg. & Quality Off.

Sold 4,500 shs ($2.02M)

Type	Security	Shares	Price	Value
Sale	Common Stock	4,500	$449.99	$2.02M

Holdings After Transaction: Common Stock — 46,793 shares (Direct)

Footnotes (1)

1. Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025. Open market sales reported on this line occurred at a weighted average price of $449.99 (range $449.99 to $450.00). Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Tatsis Ourania

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Reg. & Quality Off.

3. Date of Earliest Transaction (Month/Day/Year)
12/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	12/03/2025		S(1)		4,500	D	$449.99	46,793(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

2. Open market sales reported on this line occurred at a weighted average price of $449.99 (range $449.99 to $450.00).

3. Dr. Tatsis undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	12/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Vertex Pharmaceuticals (VRTX) disclose?

Vertex Pharmaceuticals disclosed that executive officer Dr. Ourania Tatsis, EVP, Chief Regulatory & Quality Officer, sold 4,500 shares of Vertex common stock in an open market transaction.

When did the Vertex (VRTX) insider stock sale occur and at what price?

The sale occurred on 12/03/2025 at a weighted average price of $449.99 per share, with individual sale prices ranging from $449.99 to $450.00.

How many Vertex (VRTX) shares does Dr. Tatsis hold after the reported sale?

Following the transaction, Dr. Tatsis beneficially owned 46,793 shares of Vertex Pharmaceuticals common stock directly.

Was the Vertex (VRTX) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states the transaction was made under Dr. Tatsis' company approved trading plan under Rule 10b5-1, which was entered into on 08/21/2025.

What additional pricing details were provided for the Vertex (VRTX) insider sale?

The filing notes the open market sales were reported at a weighted average price of $449.99, with a price range from $449.99 to $450.00, and that full information on each separate sale price will be provided upon request.

What is the role of the reporting person at Vertex Pharmaceuticals (VRTX)?

The reporting person, Dr. Ourania Tatsis, is an officer of Vertex, serving as EVP, Chief Regulatory & Quality Officer, and the reported holdings are listed as direct ownership.